Dupilumab for Asthma
What You Need to Know Before You Apply
What is the purpose of this trial?
Single center, randomized, placebo- controlled study to assess change in mucociliary clearance of moderate to severe asthma patients after treatment with dupilumab or placebo.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop your current medications, but it does require that you are on medium to high dose inhaled corticosteroids. If you are using antibiotics, oral prednisone, or certain asthma medications like dupilumab or anti-IL-5 therapies, you may need to stop those before joining.
Is Dupilumab generally safe for treating asthma?
What makes the drug Dupilumab unique for treating asthma?
Dupilumab is unique because it targets the IL-4 and IL-13 signaling pathways, which are involved in type 2 inflammation, making it effective for severe asthma that is not well-controlled by standard treatments. It is a monoclonal antibody, which means it is a type of protein designed to specifically target and block these pathways, potentially offering benefits for both eosinophilic and non-eosinophilic severe asthma.45678
What data supports the effectiveness of the drug Dupilumab for asthma?
Are You a Good Fit for This Trial?
Adults over 18 with moderate to severe asthma, who are on high doses of inhaled steroids and have specific markers indicating poor lung function (like low FEV1/FVC or high blood eosinophils). They shouldn't be very overweight, have had certain cancers recently, respiratory infections or used specific asthma drugs lately. Smokers and pregnant women are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Dupilumab or placebo for 12 weeks, with injections every 2 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Dupilumab
- Placebo
Dupilumab is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sally E. Wenzel MD
Lead Sponsor